IL161360A0 - Pharmaceutically acceptable alendronate salts in amorphous form - Google Patents

Pharmaceutically acceptable alendronate salts in amorphous form

Info

Publication number
IL161360A0
IL161360A0 IL16136002A IL16136002A IL161360A0 IL 161360 A0 IL161360 A0 IL 161360A0 IL 16136002 A IL16136002 A IL 16136002A IL 16136002 A IL16136002 A IL 16136002A IL 161360 A0 IL161360 A0 IL 161360A0
Authority
IL
Israel
Prior art keywords
pharmaceutically acceptable
amorphous form
acceptable alendronate
salts
alendronate salts
Prior art date
Application number
IL16136002A
Other languages
English (en)
Original Assignee
Cipla Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9924125&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL161360(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cipla Ltd filed Critical Cipla Ltd
Publication of IL161360A0 publication Critical patent/IL161360A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3839—Polyphosphonic acids
    • C07F9/3873—Polyphosphonic acids containing nitrogen substituent, e.g. N.....H or N-hydrocarbon group which can be substituted by halogen or nitro(so), N.....O, N.....S, N.....C(=X)- (X =O, S), N.....N, N...C(=X)...N (X =O, S)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
IL16136002A 2001-10-18 2002-10-18 Pharmaceutically acceptable alendronate salts in amorphous form IL161360A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0125081A GB2383042A (en) 2001-10-18 2001-10-18 Amorphous alendronate sodium
PCT/GB2002/004730 WO2003033508A1 (en) 2001-10-18 2002-10-18 Pharmaceutically acceptable alendronate salts in amorphous form

Publications (1)

Publication Number Publication Date
IL161360A0 true IL161360A0 (en) 2004-09-27

Family

ID=9924125

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16136002A IL161360A0 (en) 2001-10-18 2002-10-18 Pharmaceutically acceptable alendronate salts in amorphous form

Country Status (22)

Country Link
US (1) US7112577B2 (ru)
EP (1) EP1436303B1 (ru)
JP (1) JP4490100B2 (ru)
KR (1) KR20040053186A (ru)
AT (1) ATE338761T1 (ru)
AU (1) AU2002334200B2 (ru)
BR (1) BR0213398A (ru)
CA (1) CA2463815C (ru)
CL (1) CL2004001372A1 (ru)
DE (1) DE60214576T2 (ru)
EC (1) ECSP045067A (ru)
ES (1) ES2271375T3 (ru)
GB (1) GB2383042A (ru)
HK (1) HK1066011A1 (ru)
IL (1) IL161360A0 (ru)
MX (1) MXPA04003549A (ru)
NZ (1) NZ532292A (ru)
PT (1) PT1436303E (ru)
RU (1) RU2334751C2 (ru)
TN (1) TNSN04067A1 (ru)
WO (1) WO2003033508A1 (ru)
ZA (1) ZA200403024B (ru)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1620284B (zh) * 2001-12-24 2010-04-28 特瓦制药工业有限公司 含有用粉末或粒状材料的压缩环状体包鞘的有效成分片芯的剂型,及其生产工艺和工具
US20040052843A1 (en) * 2001-12-24 2004-03-18 Lerner E. Itzhak Controlled release dosage forms
ITMI20020146A1 (it) * 2002-01-29 2003-07-29 Lyogen Ltd Alendronato monosodico amorfo e processo per la sua preparazione
UA83900C2 (en) † 2004-02-26 2008-08-26 ЗЕНТИВА, а.с. Amorphous forms of risedronate monosodium
DE602005001873T2 (de) 2004-03-03 2008-04-24 Chemi S.P.A., Cinisello Balsamo Amorphe 3-Pyridyl-1-Hydroxyethyliden-1,1-Bisphosphonsäure Mononatriumsalz und Verfahren zu deren Herstellung
CZ297262B6 (cs) * 2004-12-28 2006-10-11 Zentiva, A. S. Trisodná sul kyseliny 4-amino-1-hydroxybutyliden-1,1-bisfosfonové
US20090118238A1 (en) * 2007-09-17 2009-05-07 Protia, Llc Deuterium-enriched alendronate
RU2015113434A (ru) * 2012-09-11 2016-11-10 Др. Редди'С Лабораторис Лимитед Полиморфные формы энзалутамида и их получение
EP3725778B1 (en) 2012-09-11 2021-08-18 Medivation Prostate Therapeutics LLC Formulations of enzalutamide
US11447506B2 (en) 2016-05-09 2022-09-20 Anacor Pharmaceuticals, Inc. Crystal forms of crisaborole in free form and preparation method and use thereof
MX2018013742A (es) * 2016-05-09 2019-08-01 Anacor Pharmaceuticals Inc Formas cristalinas de crisaborol en forma libre, metodo de preparacion y uso de las mismas.
CA3026885A1 (en) * 2016-06-16 2017-12-21 Xenon Pharmaceuticals Inc. Solid state forms of spiro-oxindole compounds
JP2019526637A (ja) * 2016-09-06 2019-09-19 インデナ・ソチエタ・ペル・アチオニ 固体形態のインゲノール ３−（３，５−ジエチルイソオキサゾール−４−カルボキシラート）及びその調製方法
EA037868B1 (ru) 2016-09-07 2021-05-28 Атеа Фармасьютикалс, Инк. 2'-замещенные-n6-замещенные пуриновые нуклеотиды для лечения вызванных рнк-вирусом заболеваний
US10336679B2 (en) * 2016-10-24 2019-07-02 Syneurx International (Taiwan) Corp. Polymorphic forms of sodium benzoate and uses thereof
US11369579B2 (en) 2016-10-24 2022-06-28 Syneurx International (Taiwan) Corp. Polymorphic forms of sodium benzoate and uses thereof
JP7066728B2 (ja) 2017-02-01 2022-05-13 アテア ファーマシューティカルズ， インコーポレイテッド Ｃ型肝炎ウイルスの治療のためのヌクレオチドヘミ硫酸塩
CN110446705B (zh) * 2017-03-30 2023-04-14 默克专利股份公司 (s)-[2-氯-4-氟-5-(7-吗啉-4-基喹唑啉-4-基)苯基]-(6-甲氧基-哒嗪-3-基)甲醇的固体形式
MX2020005348A (es) * 2017-11-22 2020-08-13 Agios Pharmaceuticals Inc Formas cristalinas de la n-(4-(4-(ciclopropilmetil)piperazin-1-car bonil)fenil)quinolin-8-sulfonamida.
CN112351799A (zh) 2018-04-10 2021-02-09 阿堤亚制药公司 具有硬化的hcv感染患者的治疗
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
WO2022176017A1 (ja) * 2021-02-16 2022-08-25 大塚製薬株式会社 非晶質体及び当該非晶質体を含む組成物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4304734A (en) * 1980-10-16 1981-12-08 Vysoka Skola Chemicko-Technologicka 6-Amino-1-hydroxyhexylidene diphosphonic acid, salts and a process for production thereof
US4922007A (en) 1989-06-09 1990-05-01 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof
ES2236737T3 (es) * 1995-06-06 2005-07-16 MERCK & CO., INC. Formulaciones de sal de alendronato monosodico anhidro y su uso en el tratamiento de enfermedades oseas.
US5853759A (en) * 1996-05-17 1998-12-29 Merck & Co.. Inc. Effervescent alendronate formulation
WO2000012517A1 (en) * 1998-08-27 2000-03-09 Teva Pharmaceutical Industries Ltd. Novel hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof
US6160165A (en) * 1998-12-10 2000-12-12 Aesgen, Inc. Method for preparation of disodium pamidronate
WO2000034293A1 (en) 1998-12-10 2000-06-15 Aesgen, Inc. Method for preparation of disodium pamidronate
AU7902800A (en) * 1999-10-26 2001-05-08 A/S Gea Farmaceutisk Fabrik Novel salts of 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid, their preparation and use

Also Published As

Publication number Publication date
RU2004113306A (ru) 2005-10-10
RU2334751C2 (ru) 2008-09-27
TNSN04067A1 (en) 2006-06-01
ECSP045067A (es) 2004-07-23
CA2463815C (en) 2009-04-07
US7112577B2 (en) 2006-09-26
ES2271375T3 (es) 2007-04-16
DE60214576T2 (de) 2007-08-30
ZA200403024B (en) 2005-03-30
JP4490100B2 (ja) 2010-06-23
KR20040053186A (ko) 2004-06-23
HK1066011A1 (en) 2005-03-11
GB0125081D0 (en) 2001-12-12
DE60214576D1 (de) 2006-10-19
EP1436303A1 (en) 2004-07-14
EP1436303B1 (en) 2006-09-06
JP2005521636A (ja) 2005-07-21
BR0213398A (pt) 2005-01-11
WO2003033508A1 (en) 2003-04-24
GB2383042A (en) 2003-06-18
CA2463815A1 (en) 2003-04-24
CL2004001372A1 (es) 2005-05-06
NZ532292A (en) 2005-07-29
PT1436303E (pt) 2006-12-29
MXPA04003549A (es) 2004-07-22
AU2002334200B2 (en) 2008-04-03
ATE338761T1 (de) 2006-09-15
US20040259846A1 (en) 2004-12-23

Similar Documents

Publication Publication Date Title
IL161360A0 (en) Pharmaceutically acceptable alendronate salts in amorphous form
HUS000494I2 (hu) Tenofovir alafenamid vagy sója, elõnyösen tenofovir alafenamid fumarát
PL364223A1 (en) Pharmaceutical salts
AUPQ750500A0 (en) A power supply
IL153882A0 (en) Valsartan salts
NO20022822D0 (no) Kraftforsyningssystem for en brönn
AU2599701A (en) A 3d camera
AU2001230477A1 (en) Active aid for a handheld camera
AU2003214024A1 (en) A 3d track ball system
IL159698A0 (en) Novel anticonvulsant derivative salts
AU2001253027A8 (en) A hybrid tracking system
PL373794A1 (en) New salts
AU2003227517A1 (en) Pharmacologically active salts
AUPQ787500A0 (en) A power supply altering means
AU2002213049A1 (en) Generating an order plan for a supply chain network
IL144444A0 (en) New morpholinobenzamide salts
AU2001230213A1 (en) Power supply unit for a decentralized power supply
AU2003247301A1 (en) Fumarate salts
GB0206708D0 (en) Pharmaceutical salts
TW555276U (en) A polarized superfluorescent fiber source configuration
AU2002328828A1 (en) Calcium salts with cytotoxic activity
AU2003245228A1 (en) Maleate salts
AU2002363009A1 (en) Generator for a hydro-electric station
AU2002253076A1 (en) Pharmaceutical salts
AU2002247745A1 (en) Pharmaceutical salts

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees